SCHEMBL31567153

SCHEMBL31567153

CNC(C#N)CCOCc1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 1/20 0.42
▸ CTSL P07711 5/20 0.41
▸ CTSS P25774 4/20 0.41
▸ CTSK P43235 4/20 0.41
▸ NAAA Q02083 1/20 0.39
▸ CTSB P07858 3/20 0.38
▸ HTT P42858 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CTSC P53634 2/20 0.37
▸ LTA4H P09960 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ SGMS2 Q8NHU3 1/20 0.37
▸ CYP2C19 P33261 1/20 0.36
▸ MMP3 P08254 1/20 0.36
▸ MMP9 P14780 1/20 0.36
▸ MMP8 P22894 1/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL75850 0.84 CTSS (0.51) TSHRCTSLCTSSCTSKCTSB
SCHEMBL10657232 0.79 TSHR (0.47) TSHRCTSLCTSKNAAACTSB
SCHEMBL30868576 0.79 TSHR (0.47) TSHRCTSLCTSSCTSKNAAA
SCHEMBL14139311 0.79 TSHR (0.47) TSHRCTSLCTSSCTSKNAAA
SCHEMBL28855532 0.75 TSHR (0.42) TSHRCTSLCTSSCTSKNAAA
SCHEMBL25055443 0.74 CTSC (0.54) CTSLCTSSCTSKCTSC
SCHEMBL7512123 0.74 CTSC (0.54) CTSLCTSSCTSKCTSC
SCHEMBL2628026 0.74 TSHR (0.45) TSHRCTSLCTSSCTSKNAAA
SCHEMBL17710656 0.74 CTSS (0.43) TSHRCTSLCTSSCTSKNAAA
SCHEMBL17710654 0.74 CTSS (0.43) TSHRCTSLCTSSCTSKNAAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473285-B2 DCN-1 modulating compounds and methods of use thereof CELLARITY, INC. (US) 2025-11-18 — — US disclosed
US-20250257063-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-08-14 — — US disclosed
US-20250163057-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF THAMES PHARMA PARTNERS 2025-05-22 — — US disclosed
WO-2025096956-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF CELLARITY, INC. (US) 2025-05-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473285-B2 DCN-1 modulating compounds and methods of use thereof DCUN1D1, DCUN1D2, DCUN1D4 TSHR 4694/4885CTSL 3240/4885CTSS 4331/4885
US-20250163057-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF DCUN1D1, DCUN1D2, DCUN1D4 TSHR 4694/4885CTSL 3240/4885CTSS 4331/4885
US-20250257063-A1 DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF DCUN1D1, DCUN1D2, DCUN1D4 TSHR 4694/4885CTSL 3240/4885CTSS 4331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback